$2.27 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 65.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ENDP | Sell | ENDO INT PLC | $85,436,000 | +8.6% | 4,240,000 | -16.0% | 3.76% | -1.2% |
| CSII | Sell | CARDIOVASCULAR SYSTEMS INC | $71,220,000 | -5.5% | 3,000,000 | -26.8% | 3.13% | -14.0% |
| LIVN | Sell | LIVANOVA PLC | $60,110,000 | -0.3% | 1,000,000 | -16.7% | 2.64% | -9.3% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $54,976,000 | -9.1% | 3,200,000 | -24.7% | 2.42% | -17.3% |
| VRX | Sell | VALEANT PHARMACEUTICALS INT (USA) | $31,215,000 | -6.4% | 1,271,500 | -23.2% | 1.37% | -14.9% |
| NVTA | Sell | INVITAE CORP | $21,393,000 | +5.4% | 2,442,122 | -11.1% | 0.94% | -4.1% |
| ELGX | Sell | ENDOLOGIX INC | $12,800,000 | -65.8% | 1,000,000 | -66.7% | 0.56% | -68.8% |
| EPRSQ | Exit | EPIRUS BIOPHARMACEUTICALS | $0 | – | -1,847,500 | -100.0% | -0.04% | – |
| OSUR | Exit | ORASURE TECHNOLOGIES INC | $0 | – | -707,559 | -100.0% | -0.20% | – |
| GNMK | Exit | GENMARK DIAGNOSTICS | $0 | – | -649,097 | -100.0% | -0.27% | – |
| BIOL | Exit | BIOLASE INC | $0 | – | -5,332,394 | -100.0% | -0.30% | – |
| DRRX | Exit | DURECT CORP COM | $0 | – | -6,000,000 | -100.0% | -0.35% | – |
| SQNM | Exit | SEQUENOM INC | $0 | – | -17,325,000 | -100.0% | -0.76% | – |
| ARIA | Exit | ARIAD PHARMACEUTICALS INC | $0 | – | -4,000,000 | -100.0% | -1.43% | – |
| WMGI | Exit | WRIGHT MEDICAL GROUP NV | $0 | – | -2,475,000 | -100.0% | -2.08% | – |
| NUVA | Exit | NUVASIVE INC. | $0 | – | -750,000 | -100.0% | -2.16% | – |
| ABC | Exit | AMERISOURCEBERGEN CORP | $0 | – | -625,000 | -100.0% | -2.40% | – |
| LDRH | Exit | LDR HOLDING CORP | $0 | – | -1,375,000 | -100.0% | -2.46% | – |
| CI | Exit | CIGNA CORP | $0 | – | -500,000 | -100.0% | -3.09% | – |
| BIIB | Exit | BIOGEN IDEC INC | $0 | – | -275,000 | -100.0% | -3.21% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.